Edwards Lifesciences Corporation Statistics
Share Statistics
Edwards Lifesciences Corporation has 589.80M shares outstanding. The number of shares has increased by -0.91% in one year.
| Shares Outstanding | 589.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.03% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 579.56M |
| Failed to Deliver (FTD) Shares | 339 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.70M, so 1.3% of the outstanding shares have been sold short.
| Short Interest | 7.70M |
| Short % of Shares Out | 1.3% |
| Short % of Float | 1.33% |
| Short Ratio (days to cover) | 1.31 |
Valuation Ratios
The PE ratio is 32.99 and the forward PE ratio is 26.86. Edwards Lifesciences Corporation's PEG ratio is 0.95.
| PE Ratio | 32.99 |
| Forward PE | 26.86 |
| PS Ratio | 7.7 |
| Forward PS | 7.2 |
| PB Ratio | 6.96 |
| P/FCF Ratio | 73.49 |
| PEG Ratio | 0.95 |
Enterprise Valuation
Edwards Lifesciences Corporation has an Enterprise Value (EV) of 45.81B.
| EV / Earnings | 32.67 |
| EV / Sales | 7.63 |
| EV / EBITDA | 25.92 |
| EV / EBIT | 29.86 |
| EV / FCF | 72.77 |
Financial Position
The company has a current ratio of 3.38, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.38 |
| Quick Ratio | 2.4 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.55 |
| Cash Flow / Debt | 1.44 |
| Interest Coverage | 87.16 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 18.12%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 0.15% |
| Return on Capital (ROIC) | 18.12% |
| Revenue Per Employee | 303.27K |
| Profits Per Employee | 70.83K |
| Employee Count | 19.80K |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | 198.70M |
| Effective Tax Rate | 0.12 |
Stock Price Statistics
The stock price has increased by -4.64% in the last 52 weeks. The beta is 1.12, so Edwards Lifesciences Corporation's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -4.64% |
| 50-Day Moving Average | 69.12 |
| 200-Day Moving Average | 78.7 |
| Relative Strength Index (RSI) | 62.85 |
| Average Volume (20 Days) | 5.75M |
Income Statement
In the last 12 months, Edwards Lifesciences Corporation had revenue of $6.00B and earned $1.40B in profits. Earnings per share was $2.31.
| Revenue | 6.00B |
| Gross Profit | 4.63B |
| Operating Income | 1.53B |
| Net Income | 1.40B |
| EBITDA | 1.77B |
| EBIT | 1.53B |
| Earnings Per Share (EPS) | 2.31 |
Balance Sheet
The company has $1.14B in cash and $694.90M in debt, giving a net cash position of $449.10M.
| Cash & Cash Equivalents | 1.14B |
| Total Debt | 694.90M |
| Net Cash | 449.10M |
| Retained Earnings | 8.99B |
| Total Assets | 12.97B |
| Working Capital | 4.78B |
Cash Flow
In the last 12 months, operating cash flow was $895.80M and capital expenditures -$266.30M, giving a free cash flow of $629.50M.
| Operating Cash Flow | 895.80M |
| Capital Expenditures | -266.30M |
| Free Cash Flow | 629.50M |
| FCF Per Share | 1.04 |
Margins
Gross margin is 77.02%, with operating and profit margins of 25.55% and 23.35%.
| Gross Margin | 77.02% |
| Operating Margin | 25.55% |
| Pretax Margin | 26.61% |
| Profit Margin | 23.35% |
| EBITDA Margin | 29.44% |
| EBIT Margin | 25.55% |
| FCF Margin | 10.48% |
Dividends & Yields
EW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.15% |
| FCF Yield | 1.46% |
Analyst Forecast
The average price target for EW is $76.5, which is 4.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $76.5 |
| Price Target Difference | 4.3% |
| Analyst Consensus | Hold |
| Analyst Count | 21 |
Stock Splits
The last stock split was on Jun 1, 2020. It was a forward split with a ratio of 3:1.
| Last Split Date | Jun 1, 2020 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | 10.44 |
| Piotroski F-Score | 6 |